94 related articles for article (PubMed ID: 16007127)
21. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T
Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303
[TBL] [Abstract][Full Text] [Related]
22. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
[TBL] [Abstract][Full Text] [Related]
23. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion.
Lane SW; Fairbairn DJ; McCarthy C; Nandini A; Perry-Keene J; Kennedy GA
Br J Haematol; 2008 Aug; 142(4):503. PubMed ID: 18537978
[No Abstract] [Full Text] [Related]
24. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
25. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.
Impera L; Lonoce A; Fanfulla DA; Moreilhon C; Legros L; Raynaud S; Storlazzi CT
Cancer Genet; 2011 Sep; 204(9):512-5. PubMed ID: 22018274
[TBL] [Abstract][Full Text] [Related]
26. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes.
Dargent JL; Mathieux V; Vidrequin S; Deghorain X; Vannuffel P; Rack K
Eur J Haematol; 2011 Jan; 86(1):87-90. PubMed ID: 21070368
[No Abstract] [Full Text] [Related]
27. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Tefferi A; Gilliland G
Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
[TBL] [Abstract][Full Text] [Related]
28. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
Saglio G; Morotti A; Mattioli G; Messa E; Giugliano E; Volpe G; Rege-Cambrin G; Cilloni D
Ann N Y Acad Sci; 2004 Dec; 1028():423-31. PubMed ID: 15650267
[TBL] [Abstract][Full Text] [Related]
29. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia.
Kratz CP; Böll S; Kontny U; Schrappe M; Niemeyer CM; Stanulla M
Leukemia; 2006 Feb; 20(2):381-3. PubMed ID: 16341038
[No Abstract] [Full Text] [Related]
30. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia.
dos Santos NR; Ghysdael J
Leukemia; 2006 Jan; 20(1):182-5. PubMed ID: 16281066
[No Abstract] [Full Text] [Related]
31. A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea.
Song I; Lee DH; Lee JH; Jang S; Huh JR; Seo EJ
Ann Lab Med; 2016 Jan; 36(1):79-81. PubMed ID: 26522767
[No Abstract] [Full Text] [Related]
32. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.
Cilloni D; Carturan S; Bracco E; Campia V; Rosso V; Torti D; Calabrese C; Gaidano V; Niparuck P; Favole A; Signorino E; Iacobucci I; Morano A; De Luca L; Musto P; Frassoni F; Saglio G
Leuk Res; 2013 May; 37(5):520-30. PubMed ID: 23415111
[TBL] [Abstract][Full Text] [Related]
33. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract][Full Text] [Related]
34. Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.
Huang KP; Chase AJ; Cross NCP; Reiter A; Li TY; Wang TF; Chu SC; Lu XY; Li CC; Kao RH
Int J Hematol; 2008 Sep; 88(2):197-201. PubMed ID: 18594780
[TBL] [Abstract][Full Text] [Related]
35. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders.
Cazzola M; Skoda R
Haematologica; 2005 Jul; 90(7):871-4. PubMed ID: 15996923
[No Abstract] [Full Text] [Related]
36. Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.
Onnebo SM; Rasighaemi P; Kumar J; Liongue C; Ward AC
Haematologica; 2012 Dec; 97(12):1895-903. PubMed ID: 22733019
[TBL] [Abstract][Full Text] [Related]
37. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
[TBL] [Abstract][Full Text] [Related]
38. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Levine RL; Loriaux M; Huntly BJ; Loh ML; Beran M; Stoffregen E; Berger R; Clark JJ; Willis SG; Nguyen KT; Flores NJ; Estey E; Gattermann N; Armstrong S; Look AT; Griffin JD; Bernard OA; Heinrich MC; Gilliland DG; Druker B; Deininger MW
Blood; 2005 Nov; 106(10):3377-9. PubMed ID: 16081687
[TBL] [Abstract][Full Text] [Related]
39. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
Sulong S; Case M; Minto L; Wilkins B; Hall A; Irving J
Br J Haematol; 2005 Sep; 130(6):964-5. PubMed ID: 16156866
[No Abstract] [Full Text] [Related]
40. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.
Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E
Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
